Clinical Trials
30 trialsManagement of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
Sir Mortimer B. Davis - Jewish General Hospital
DASL-HiCaP
University of Sydney
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
GETUG-AFU 40
UNICANCER
PICASSO
St Vincent's Hospital, Sydney
DIVINE
Mayo Clinic
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Swiss Cancer Institute
THUNDER
Cancer Research Antwerp
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
Dana-Farber Cancer Institute
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
Beth Israel Deaconess Medical Center
ExBAT
Latin American Cooperative Oncology Group
COAction
Brazilian Clinical Research Institute
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
AdventHealth
Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
University of Chicago
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
Peking University First Hospital
ARACOG
Alliance Foundation Trials, LLC.
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vanderbilt-Ingram Cancer Center
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
Qilu Hospital of Shandong University
DECREASE
Trans Tasman Radiation Oncology Group
PEACE 7
UNICANCER